Effect of Preventional Drug Therapy on Pain Regulation Mechanisms Among SCI
Status:
Unknown status
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
Central neuropathic pain (CNP) is defined as chronic pain due to injury or disease in the
central nervous system. This pain is most common among people with a spinal cord injuries
(SCI), with a prevalence of about 50%. The central pain usually develops within a few months
of spinal cord injury - and this period is significance in terms of this research work. This
pain is one of the most complex and challenging pain syndromes. One of the reasons for this
stems from its adherence to most treatments. Another reason is that there is partial
information about the mechanism responsible for its development. Animal studies suggest that
it is possible to prevent and / or reduce its development or reduce its strength by
preventive treatment (given immediately after the injury). Currently, the treatments found to
prevent or reduce central pain in animals are anti Inflammation and neuronal excitability
suppressors such as interleukin 10.
The purpose of this study,is to explore whether pre-treatment with pregabalin prior to the
development of the central pain will prevent the incidence of pain or reduce its intensity by
improving pain regulation and reducing hypersensitivity.
The goal of the pharmacotherapy is to reduce the hypersensitivity- lyrica is used to reduce
chronic neuropathic pain by reducing the degree of hypersensitivity in the pain system.
the objectives of this study are to examine whether early treatment of central pain can
prevent or reduce the incidence of pain by improving pain regulation and reducing
hypersensitivity. That is, whether there will be a difference between those who take
Lyrica-Pregabalin (a drug that reduces hypersensitivity of pain) compared to placebo.
Methods: A randomized, double-blind, placebo-controlled study in which people with a fresh
SCI will receive lyrica or placebo as soon as possible from their arrival at the
rehabilitation hospital for 2-3 months during which pain system characteristics will be
measured and monitored for central pain development.